Search results
Results from the WOW.Com Content Network
The initial treatment for endometrial cancer is surgery; 90% of women with endometrial cancer are treated with some form of surgery. [23] Surgical treatment typically consists of hysterectomy including a bilateral salpingo-oophorectomy , which is the removal of the uterus, and both ovaries and Fallopian tubes.
Treatment of uterine cancer may differ depending on the type of cancer and staging of the tumor. [15] In early stages, minimal invasive surgery is preferred. [16] For endometrial cancer, five main types of treatments are used, including surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy
Endometrial cancer ranks as the fourth most prevalent cancer among women in the U.S. In 2022, it affected more than 66,000 patients and was responsible for nearly 12,000 fatalities.
Gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. As specialists, they have extensive training in the diagnosis and treatment of cancers.
Uterine clear cell carcinoma is a rare, aggressive form of endometrial cancer. This is an example of a Type II endometrial carcinoma, meaning that it is unrelated to endometrial hyperplasia. Uterine clear cell tumors arise from an endometrium that has become thin and dry. [7] Patients usually present with abnormal uterine bleeding.
Tamoxifen is currently first-line treatment for nearly all pre-menopausal women with hormone receptor-positive breast cancer. [1] Raloxifene is another partial agonist SERM which does not seem to promote endometrial cancer, and is used primarily for chemoprevention of breast cancer in high-risk individuals, as well as to prevent osteoporosis. [1]
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. [5] [6] [10] Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
(Reuters) -Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line treatment for a type of cancer in the uterus lining.